Pfizer Plans to Launch Anti-Smoking Chantix in India by End of February
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - On the heels of a study showing one million people die yearly in India from smoking-related illness, Pfizer plans to launch its anti-smoking tablet Chantix (varenicline) by the end of the month, Pfizer India told PharmAsia News
You may also be interested in...
Pfizer Pushes Champix In India Through Private Hospitals And Clinics As Smoking Epidemic Hits India
MUMBAI - A smoking epidemic that kills nearly a million people in India every year has led Pfizer to get aggressive on collaborating with private sector healthcare units to open 600 smoking cessation clinics in the next two years
Pfizer Pushes Champix In India Through Private Hospitals And Clinics As Smoking Epidemic Hits India
MUMBAI - A smoking epidemic that kills nearly a million people in India every year has led Pfizer to get aggressive on collaborating with private sector healthcare units to open 600 smoking cessation clinics in the next two years
Pfizer’s Champix Approved In Japan
TOKYO - Pfizer is hoping to launch its smoking cessation aid Champix (varenicline) in Japan in April after receiving manufacturing and marketing approval from the Ministry of Health Labor and Welfare Jan. 25, Pfizer Japan told PharmAsia News